NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
Primary Purpose
Thalassemia Major
Status
Not yet recruiting
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
n-acetylcystine
Sponsored by
About this trial
This is an interventional supportive care trial for Thalassemia Major focused on measuring N_acetylcystein antioxidant effect
Eligibility Criteria
Inclusion Criteria: thalassemia major children . On oral iron chelation . Exclusion Criteria: change in the dose of iron chelation within 3 months before enrollement or during study period . Liver impairment Renal impairment patients not adeherent to therapy
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
N_acetylcystein as antioxidant on iron and frequency of blood transfusion in thalassemia major
Arm Description
N_acetylcystein administration on single oral dose 10mg /kg for 6 months and it's effect on iron and frequency of blood transfusion before and after its use.
Outcomes
Primary Outcome Measures
Serum ferritin level
Measuring serum ferritin level (mg/dl) before and after 6 months of acetylcystein administration.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05777733
Brief Title
NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
Official Title
The Effect of N_acetylcystein as an Antioxidant on Iron Overload and Frequency of Blood Transfusion in β-thalassemia Major Patients at Assiut Childern Hospital University
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 23, 2024 (Anticipated)
Primary Completion Date
April 30, 2024 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The effect of N_acetylcystein as an antioxidant on iron overload and frequency of blood transfusion in β-thalassemia major patients at Assiut Childern Hospital University And its cosubmitted for partial fulfillment of master degree in Pediatrics
Detailed Description
Beta thalassemia major it menifests after 6 months of life by severe anemia requiring life-long blood transfusion,which is the the gold standard therapy causing many complications including iron overload which associated to a certain extent with the generation of labile iron in the pathological red blood cell (RBC). The appearance of such forms of iron at the inner and outer cell surfaces exposes the cell to formation of reactive oxygen species (ROS),particularly the hydroxyl radical (·OH) serving as a Fenton reagent, Hydroxyl radical facilitated by membraneassociated iron might be particularly harmful because radical generation would be relatively sequestered from the cell antioxidant capacity and occur directly adjacent to lipid and protein membrane components exceeding cellular defense capacities causing oxidtive stress with prematre cell damage which is the main pathophysiological process in thalassemia . the fact that iron plays a major role in the generation of ROS implies that iron chelators can also serve as antioxidants. Obviously, chelation of iron is one of the major therapeutic goals in thalassemia. Consequently, the orally administered iron chelator deferiprone was able to remove free iron from β- thalassemic red cell membranes in a dose-related fashion, Deferiprone alleviated membrane damage possibly mediated by catalytic iron, such as In a few patients with Hb E/β thalassemia in Thailand, following administration of deferiprone alone for an average of 50 weeks, Hb levels increased concomitant with a decrease in transfusion requirement One possible explanation for this finding is that deferiprone acted like an antioxidant by removing excess free iron from the cells and, as a result, ROS generation was decreased. However, the antioxidant effect of this iron chelator by itself was not sufficient to neutralize the damage induced by ROS Moreover, oral administration of other antioxidant such as vitamin E, which is a lipid antioxidant, exhibited improvement in oxidant-antioxidant balance in the plasma . Another antioxidant that acts primarily on proteins is n_acetylcysteine, which improved certain parameters resulting from oxidative damage to sickle RBCs. here we will give the N_acetylcysteine orally in dose 10mg\kg\day to the thalassemic patients for 6 months and observing its effect as antioxidant on iron overload and the frequency in blood transfusion The ultimate purpose of all these observations is to try to design a combination of antioxidants consisting of an iron chelator, such as deferiprone, vitamin E as antioxidant for the lipids, and N-acetylcysteine as antioxidant for the proteins to decrease the deleterious effect of ORS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thalassemia Major
Keywords
N_acetylcystein antioxidant effect
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Model Description
N-acetylcystein in dose 10mg /kg single oral dose will be given for 6 months
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
N_acetylcystein as antioxidant on iron and frequency of blood transfusion in thalassemia major
Arm Type
Experimental
Arm Description
N_acetylcystein administration on single oral dose 10mg /kg for 6 months and it's effect on iron and frequency of blood transfusion before and after its use.
Intervention Type
Drug
Intervention Name(s)
n-acetylcystine
Other Intervention Name(s)
acetylcystein
Intervention Description
Single daily oral administration of N_acetylcystein on dose 10mg /kg/day
Primary Outcome Measure Information:
Title
Serum ferritin level
Description
Measuring serum ferritin level (mg/dl) before and after 6 months of acetylcystein administration.
Time Frame
6 months from the baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
thalassemia major children .
On oral iron chelation .
Exclusion Criteria:
change in the dose of iron chelation within 3 months before enrollement or during study period .
Liver impairment
Renal impairment
patients not adeherent to therapy
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33147909
Citation
Mohamed YA, Meabed MH, Ashraf A, Morgan DS, Abdul Latif MG, Abd-Elkareem RM, Ahmed HM. WITHDRAWN:Randomized controlled trial of effect of N-acetylcysteine as an antioxidant on iron overload in children with thalassemia major. Clin Exp Pediatr. 2020 Nov 3. doi: 10.3345/cep.2020.00227. Online ahead of print.
Results Reference
background
Learn more about this trial
NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
We'll reach out to this number within 24 hrs